Several studies demonstrated alterations of gene expression in blood in various neurological disorders including Huntington's disease (HD). The aim of our study was to validate gene expression changes in a cohort of HD patients and evaluate their sensitivity and specificity. Four different groups were included: patients with HD, Parkinson's disease (PD), acute ischemic stroke (AS) and healthy controls. Gene expression changes in HD blood partly overlapped with those observed in blood from PD and AS patients. Predictive value for HD group was 78%, with 82% sensitivity and 53% specificity rate.
COBISS.SI-ID: 26255065
Frst effective drugs for Parkinson's disease (PD) were the anticholinergics. Since the introduction of levodopa in the sixties of the previous century, many new drugs have emerged for the treatment of Parkinson's disease. In all stages of the disease, levodopa remains the most effective drug. However, long term treatment with levodopa is accompanied by the development of motor fluctuations and other neurological signs. Some of these drugs have caused considerable concern and controversies and were regarded at as the 'bad guys' of Parkinson's disease pharmacological armamentarium.
COBISS.SI-ID: 26254553